LOGIN  |  REGISTER
Assertio
Terns Pharmaceuticals

Myriad Genetics Included in Forbes America’s Best Employers 2025 List

February 19, 2025 | Last Trade: US$11.00 0.75 7.32

SALT LAKE CITY, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, has been named on the Forbes list of America’s Best Employers 2025. This prestigious recognition is presented in collaboration with Statista, the world-leading statistics portal and industry ranking provider.

“Working at Myriad Genetics means being part of a dynamic team dedicated to empowering every individual by revealing the answers inside each of us. Our teammates are driven to innovate solutions that change lives,” said Shereen Solaiman, chief people officer, Myriad Genetics. “I want to commend our teammates, who are dedicated to advancing health and wellbeing for all.”

Being included on the Forbes list is the latest accolade for the company. Last year, 84% of Myriad employees said it’s a Great Place To Work — 27 percentage points higher than the average U.S. company.

Forbes and Statista selected America’s Best Employers 2025 through an independent survey from a vast sample of more than 217,000 U.S. employees working for companies employing at least 1,000 people within the U.S. More than 6.5 million employer evaluations were considered. The final score is based on two types of evaluations: personal (those given by employees themselves) and public (those given by friends and family members of employees, or members of the public who work in the same industry), with a much higher weighting for personal evaluations.

For more information about careers at Myriad, please visit: https://myriad.com/careers/.

About Statista

Statista publishes hundreds of worldwide industry rankings and company listings with high-profile media partners. This research and analysis service is based on the success of statista.com, the leading data and business intelligence portal that provides statistics, business-relevant data, and various market and consumer studies and surveys.

About Myriad Genetics

Myriad Genetics is a leading genetic and genomic tumor testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

Investor Contact
Matt Scalo
(801) 584-3532
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact
Kate Schraml
(224) 875-4493
This email address is being protected from spambots. You need JavaScript enabled to view it.

Assertio

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page